Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 12:41 AM ET

Healthcare Equipment and Supplies

Company Overview of Arch Therapeutics, Inc.

Company Overview

Arch Therapeutics, Inc. operates as a life science medical device company. The company focuses on developing products by utilizing a novel approach to stop bleeding and control leaking during surgery and trauma care. Its lead product candidate includes AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide, which comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Wellesley, Massachusetts.

20 William Street

Suite 270

Wellesley, MA 02481

United States

Founded in 2006

5 Employees



Key Executives for Arch Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $402.0K
Chief Financial Officer and Treasurer
Age: 57
Total Annual Compensation: $267.5K
Compensation as of Fiscal Year 2015.

Arch Therapeutics, Inc. Key Developments

Arch Therapeutics, Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 03:30 PM

Arch Therapeutics, Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 03:30 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Terrence W. Norchi, Co-Founder, Chief Executive Officer, President and Director.

Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device in Preclinical Toxicity Test of Sensitization

Arch Therapeutics, Inc. obtained favorable data from a preclinical toxicology test for AC5™ showing that the device did not cause sensitizing reactions in animals and is considered a 'non-sensitizer'. The test, called the Maximization Test, is a standardized test of contact sensitization and is performed in animals as a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5 is a development-stage hemostasis product being evaluated to control bleeding, mitigate fluid loss, and create an environment permissive to normal healing in order to provide more efficient surgical and interventional care. In this standard in vivo study, designed to provide general information on the health hazards likely to arise from acute exposure to clinically relevant quantities of AC5, AC5 was well tolerated when using standardized success criteria based upon comparison with control materials. As a result, AC5 was classified as a non-sensitizer with no evidence of causing delayed contact sensitization. Results from this biocompatibility safety study indicate that AC5’s peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound site, does not promote sensitization to the overall biological system following application of standardized AC5 extract solutions in animals. The results of this study provide further evidence of the absence of toxicity for AC5, and represent a critical step toward demonstrating biocompatibility of this medical device.

Arch Therapeutics, Inc. Appoints James Sulat as Director

Arch Therapeutics, Inc. has appointed James Sulat to its board of directors as an independent member, effective August 19, 2015. Mr. Sulat served as chief executive officer and chief financial officer of Maxygen Inc. from October 2009 to June 2013. Prior to this, he was chief executive officer, chief financial officer and a member of the board of directors at Memory Pharmaceuticals Corp. from 2005 to 2008. He previously served in senior executive roles for R.R. Donnelley & Sons Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. He currently serves as chairman of the board of directors of Momenta Pharmaceuticals, Inc. He has additionally served on numerous boards including Valneva SE, AMAG Pharmaceuticals, Inc., diaDexus, Inc., and General Surgical Innovations, Inc.

Similar Private Companies By Industry

Company Name Region
Nipro Diagnostics, Inc. United States
Lanx, Inc. United States
Quality Assured Services, Inc. United States
Middle Peak Medical Inc. United States
E-Wilson, LLC United States

Recent Private Companies Transactions

Private Placement
June 22, 2015
Private Placement
March 11, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Arch Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at